Kracov Quoted in Bloomberg BNA on Trump's FDA Nominee

March 16, 2017

Life Sciences and Healthcare Regulatory partner Daniel Kracov was quoted in a recent Bloomberg BNA article, "Trump’s FDA Nominee Spurs Concerns About Drug Approvals, Off-Label Promotion," which evaluates the strengths and weaknesses of FDA Commissioner nominee Scott Gottlieb.

» Read the full article (subscription required).


Email Disclaimer